Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

About Halia Therapeutics About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies. Halia's mission is to create data-driven therapies...

LEHI, Utah, 04/09/2025 (informazione.news - comunicati stampa - salute e benessere)

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.

Halia's mission is to create data-driven therapies that not only extend life but also improve its quality. The company is headquartered in Lehi, Utah , and is actively advancing global partnerships in clinical research, drug discovery, and personalized medicine.

To learn more, visit www.haliatx.com or follow us on LinkedIn and Twitter @HaliaTx.

Taylor Avei 
Director of Business Development
Halia Therapeutics
info@haliatx.com

Leigh Salvo 
New Street Investor Relations
leigh@newstreetir.com

Logo - https://mma.prnewswire.com/media/2702932/Halia_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference-302546094.html